MX2009009816A - Anticuerpos monoclonales para el tratamiento del cancer. - Google Patents

Anticuerpos monoclonales para el tratamiento del cancer.

Info

Publication number
MX2009009816A
MX2009009816A MX2009009816A MX2009009816A MX2009009816A MX 2009009816 A MX2009009816 A MX 2009009816A MX 2009009816 A MX2009009816 A MX 2009009816A MX 2009009816 A MX2009009816 A MX 2009009816A MX 2009009816 A MX2009009816 A MX 2009009816A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
monoclonal antibodies
therapeutics
treating
Prior art date
Application number
MX2009009816A
Other languages
English (en)
Inventor
Ugur Sahin
Oezlem Tuereci
Michael Koslowski
Original Assignee
Ganymed Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ganymed Pharmaceuticals Ag filed Critical Ganymed Pharmaceuticals Ag
Publication of MX2009009816A publication Critical patent/MX2009009816A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)

Abstract

La presente invención proporciona anticuerpos útiles como agentes terapéuticos para el tratamiento y/o prevención de enfermedades asociadas con la expresión celular de GT468, incluyendo enfermedades relacionadas con tumores como el cáncer de seno, cáncer de pulmón, cáncer gástrico, cáncer de ovarios y cáncer hepatocelular.
MX2009009816A 2007-03-14 2008-03-14 Anticuerpos monoclonales para el tratamiento del cancer. MX2009009816A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89486007P 2007-03-14 2007-03-14
EP07005258A EP1970384A1 (en) 2007-03-14 2007-03-14 Monoclonal antibodies for treatment of cancer
PCT/EP2008/002063 WO2008110379A2 (en) 2007-03-14 2008-03-14 Monoclonal antibodies for treatment of cancer

Publications (1)

Publication Number Publication Date
MX2009009816A true MX2009009816A (es) 2009-11-23

Family

ID=38134942

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009816A MX2009009816A (es) 2007-03-14 2008-03-14 Anticuerpos monoclonales para el tratamiento del cancer.

Country Status (25)

Country Link
US (4) US8354104B2 (es)
EP (3) EP1970384A1 (es)
JP (2) JP5389675B2 (es)
KR (2) KR101567494B1 (es)
CN (2) CN105131115A (es)
AU (1) AU2008226001B2 (es)
BR (1) BRPI0808814A2 (es)
CA (1) CA2678732C (es)
CY (1) CY1120123T1 (es)
DK (1) DK2125897T3 (es)
ES (1) ES2664571T3 (es)
HR (1) HRP20180485T1 (es)
HU (1) HUE037671T2 (es)
IL (1) IL200388A (es)
LT (1) LT2125897T (es)
MX (1) MX2009009816A (es)
NO (1) NO2125897T3 (es)
NZ (1) NZ579614A (es)
PL (1) PL2125897T3 (es)
PT (1) PT2125897T (es)
RS (1) RS57089B1 (es)
SG (1) SG10201506625VA (es)
SI (1) SI2125897T1 (es)
WO (1) WO2008110379A2 (es)
ZA (1) ZA200905833B (es)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8961980B2 (en) 2007-03-14 2015-02-24 Ganymed Pharmaceuticals Ag Monoclonal antibodies for treatment of cancer
US8975375B2 (en) 2005-09-12 2015-03-10 Ganymed Pharmaceuticals Ag Identification of tumor-associated antigens for diagnosis and therapy
US9216218B2 (en) 2010-03-23 2015-12-22 Ganymed Pharmaceuticals Ag Monoclonal antibodies for treatment of cancer

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
AU2015205868B2 (en) * 2008-09-16 2017-04-27 Ganymed Pharmaceuticals Ag Monoclonal antibodies for treatment of cancer
EP2166021A1 (en) * 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
CA2832174C (en) 2011-05-13 2024-02-27 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
CN106659785B (zh) * 2014-05-07 2021-04-30 武田有限公司 包含gm-csf中和化合物的液体制剂
EP3430166A4 (en) * 2016-03-14 2019-11-13 Curemeta Therapeutics, LLC PODOCALYXIN AND TRA ASSOCIATED ANTIBODIES, METHOD FOR THE PRODUCTION AND USE THEREOF AS THERAPEUTIC AGAINST CANCER
WO2018222506A1 (en) * 2017-05-27 2018-12-06 Immune-Onc Therapeutics, Inc. Modulation of immunoglobulin-a-positive cells
WO2023220336A1 (en) * 2022-05-13 2023-11-16 Herzlinger Regina E Methods, systems, and apparatus for administering an antibody treatment via infusion

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) * 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4439196A (en) * 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) * 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) * 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) * 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPH02500329A (ja) * 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) * 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5744585A (en) 1995-03-16 1998-04-28 Medenica; Rajko D. Human monoclonal antibody against lung carcinoma
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US20020065394A1 (en) * 1998-03-18 2002-05-30 Kenneth Jacobs Secreted proteins and polynucleotides encoding them
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9826143D0 (en) 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
AU2001280608A1 (en) 2000-07-18 2002-01-30 Curagen Corporation Human polynucleotides and polypeptides encoded thereby
AU2001284703B2 (en) 2000-08-03 2007-03-22 Therapeutic Human Polyclonals Inc. Production of humanized antibodies in transgenic animals
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
ES2295228T3 (es) 2000-11-30 2008-04-16 Medarex, Inc. Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos.
US20020177547A1 (en) 2001-01-16 2002-11-28 Karin Molling Pharmaceutical compositions for treating or preventing cancer
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CA2457819A1 (en) 2001-08-14 2003-02-27 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
WO2003075014A2 (en) * 2002-03-06 2003-09-12 Oxford Glycosciences (Uk) Ltd Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
WO2003102159A2 (en) 2002-06-04 2003-12-11 Curagen Corporation Novel proteins and nucleic acids encoding same
US7053201B2 (en) 2002-08-30 2006-05-30 National Defense Medical Center Nucleic acid molecules and polypeptides related to h-ADAM7
PT3284753T (pt) 2002-10-17 2020-05-04 Genmab As Anticorpos monoclonais humanos contra cd20 para utilização no tratamento da esclerose múltipla
EP1583846B1 (en) 2003-01-17 2011-11-16 The Chinese University Of Hong Kong Circulating mrna as diagnostic markers for pregnancy-related disorders
US20050255114A1 (en) 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
CN1663603A (zh) 2004-03-02 2005-09-07 北京大学 一种肿瘤－胎盘抗原蛋白及其dna在肿瘤治疗中的应用
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1970384A1 (en) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2221063A1 (en) * 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
HUE064745T2 (hu) * 2009-02-20 2024-04-28 Astellas Pharma Inc Módszerek és készítmények a rák diagnosztizálására és kezelésére
EP2371864A1 (en) * 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8975375B2 (en) 2005-09-12 2015-03-10 Ganymed Pharmaceuticals Ag Identification of tumor-associated antigens for diagnosis and therapy
US9919036B2 (en) 2005-09-12 2018-03-20 Ganymed Pharmaceuticals Ag Identification of tumor-associated antigens for diagnosis and therapy
US8961980B2 (en) 2007-03-14 2015-02-24 Ganymed Pharmaceuticals Ag Monoclonal antibodies for treatment of cancer
US9475867B2 (en) 2007-03-14 2016-10-25 Ganymed Pharmaceuticals Ag Monoclonal antibodies for treatment of cancer
US10125196B2 (en) 2007-03-14 2018-11-13 Ganymed Pharmaceuticals Ag Monoclonal antibodies for treatment of cancer
US9216218B2 (en) 2010-03-23 2015-12-22 Ganymed Pharmaceuticals Ag Monoclonal antibodies for treatment of cancer
US10596256B2 (en) 2010-03-23 2020-03-24 TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH Monoclonal anti-GT 468 antibodies for treatment of cancer

Also Published As

Publication number Publication date
US20100111975A1 (en) 2010-05-06
AU2008226001A1 (en) 2008-09-18
EP2125897A2 (en) 2009-12-02
EP2125897B1 (en) 2018-01-17
IL200388A0 (en) 2010-04-29
LT2125897T (lt) 2018-04-25
US20150175686A1 (en) 2015-06-25
NO2125897T3 (es) 2018-06-16
AU2008226001B2 (en) 2013-09-05
PL2125897T3 (pl) 2018-09-28
WO2008110379A8 (en) 2009-11-05
NZ579614A (en) 2012-02-24
US8961980B2 (en) 2015-02-24
SI2125897T1 (en) 2018-06-29
EP2487189B8 (en) 2019-01-09
US9475867B2 (en) 2016-10-25
HUE037671T2 (hu) 2018-09-28
KR20100014405A (ko) 2010-02-10
EP1970384A1 (en) 2008-09-17
ZA200905833B (en) 2011-02-23
US20130156782A1 (en) 2013-06-20
RS57089B1 (sr) 2018-06-29
WO2008110379A2 (en) 2008-09-18
EP2487189B1 (en) 2018-08-22
KR101567494B1 (ko) 2015-11-23
CN101754979A (zh) 2010-06-23
BRPI0808814A2 (pt) 2015-06-23
US20170058044A1 (en) 2017-03-02
IL200388A (en) 2015-08-31
US8354104B2 (en) 2013-01-15
KR20150080032A (ko) 2015-07-08
CA2678732A1 (en) 2008-09-18
ES2664571T3 (es) 2018-04-20
JP5389675B2 (ja) 2014-01-15
JP2010520910A (ja) 2010-06-17
DK2125897T3 (en) 2018-04-23
JP2013255506A (ja) 2013-12-26
US10125196B2 (en) 2018-11-13
CN101754979B (zh) 2015-04-08
CY1120123T1 (el) 2018-12-12
CA2678732C (en) 2017-12-19
EP2487189A1 (en) 2012-08-15
WO2008110379A3 (en) 2008-10-30
SG10201506625VA (en) 2015-10-29
JP5843822B2 (ja) 2016-01-13
CN105131115A (zh) 2015-12-09
PT2125897T (pt) 2018-03-29
HRP20180485T1 (hr) 2018-05-18

Similar Documents

Publication Publication Date Title
MX2009009816A (es) Anticuerpos monoclonales para el tratamiento del cancer.
EP4242236A3 (en) Monoclonal antibodies against claudin-18 for treatment of cancer
SG10201903351SA (en) Monoclonal antibodies against claudin-18 for treatment of cancer
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
IL258880A (en) Compounds of diarylhydantoin
MX2020001224A (es) Anticuerpos para el tratamiento del cancer.
MX2019009441A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2020011780A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2020011790A (es) Anticuerpos especificos para claudina 6 (cldn6).
MX357010B (es) Anticuerpos monoclonales para tratamiento de cancer.
NZ607588A (en) Antibodies against human TWEAK and uses thereof
MX337586B (es) Anticuerpos anti-interleucina-1beta para usarse en el tratamiento de condiciones relacionadas con interleucina-1beta.
WO2009124281A3 (en) Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis
NZ589795A (en) Use of LM-1 antibody which binds to NONO/nmt55 protein to prevent metastasis

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration